News - Diabetes


Current filters:


Popular Filters

400 to 424 of 429 results

US FDA advisory gives thumbs down to B-MS and AstraZeneca diabetes drug dapagliflozin on safety issues


The US Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee yesterday…

AstraZenecaBristol-Myers SquibbdapagliflozinDiabetesNorth AmericaPharmaceuticalRegulation

European Commission and Australia OK Bristol-Myers Yervoy and Novo Nordisk’s FlexTouch


Following a recent positive recommendation from the European Medicine Agency’s advisory panel, Bristol-Myers…

Bristol-Myers SquibbDiabetesEuropeFlexTouchNovo NordiskOncologyPharmaceuticalRegulationYervoy

Amylin and Lilly to re-file Bydureon with US FDA sooner than expected with new tQT data


Amylin Pharmaceuticals (Nasdaq: AMLN), Eli Lilly (NYSE: LLY) and Alkermes (Nasdaq: ALKS) have announced…

AlkermesAmylinBydureonDiabetesEli LillyPharmaceuticalRegulationResearch

Roche returns rights to SGLT2 inhibitor CSG452 for diabetes to Chugai


Swiss drug major Roche (ROG: SIX) said yesterday that it will return its development and marketing rights…

Chugai PharmaceuticalDiabetesLicensingPharmaceuticalRoche

Highlights from American Diabetes Association meeting


There was a batch of good news coming out of the American Diabetes Association (ADA) 71st annual scientific…

ApidraAstraZenecaBristol-Myers SquibbdapagliflozinDiabetesLantusLyxumiaNovo NordiskOnglyzaPharmaceuticalResearchSanofiVictoza

Eli Lilly gets EU approval for long-acting diabetes drug Bydureon


In what was excellent news for all three companies following rejections of the drug by US regulators,…

AlkermesAmylinBydureonDiabetesEli LillyEuropePharmaceuticalRegulation

Boehringer gains global rights to Zealand’s diabetes/obesity compounds in 376 million-euro deal


German independent drug major Boehringer Ingelheim has signed an exclusive global licence and collaboration…

Boehringer IngelheimDiabetesLicensingMetabolicsPharmaceuticalResearchZealand Pharma

Bladder cancer risk of Takeda’s Actos now highlighted by US FDA


The latest bad news for Japan’s largest drugmaker, Takeda Pharmaceutical (TYO: 4502) came last night…

ActosDiabetesNorth AmericaPharmaceuticalRegulationTakeda Pharmaceuticals

Boehringer Ingelheim and Lilly begin US roll-out of diabetes drug Tradjenta


German independent drug major Boehringer Ingelheim and USA-based Eli Lilly (NYSE: LLY) announced yesterday…

Boehringer IngelheimDiabetesEli LillyMarkets & MarketingNorth AmericaPharmaceuticalTradjenta

France suspends sales of Takeda’s Actos on cancer risk concerns


Sales of blockbuster diabetes drug Actos (pioglitazone), from Japan’s leading drugmaker Takeda Pharmaceuticals…

ActosDiabetesEli LillyEuropePharmaceuticalRegulationTakeda Pharmaceuticals

Asterand licenses diabetes assay platform from Capsant Neurotech


Asterand (LSE: ATD), a provider of human tissue and cell-based services to pharmaceutical and biotechnology…

AsterandBiotechnologyCapsant NeurotechnologiesDiabetesLicensing

Tianyin granted production license for diabetes drug Gliclazide by China's SFDA


Tianyin Pharmaceutical (NYSE Amex: TPI), a China-based pharmaceutical company that specializes in patented…

Asia-PacificDiabetesGliclazidePharmaceuticalRegulationTianyin Pharma

Positive Ph III results from Sanofi GetGoal Program on Lyxumia


French drug major Sanofi (Euronext: SAN) announced today that new results from a Phase III study showed…

DiabeteslixisenatideLyxumiaPharmaceuticalResearchSanofiZealand Pharma

GlaxoSmithKline’s diabetes drug Avandia to be restricted on US market


As part of a US Food and Drug Administration re-assessment of UK drug giant GlaxoSmithKline’s troubled…

AvandiaDiabetesGlaxoSmithKlineNorth AmericaPharmaceuticalRegulation

US cancer drug use and spending to rise sharply by 2013, followed by diabetes and CNS, says Medco


Expensive new cancer drugs treating increasing numbers of patients could drive cancer drug spending by…

DiabetesMarkets & MarketingNeurologicalNorth AmericaOncologyPharmaceuticalPricing

Amylin sues Eli Lilly, alleging anti-competitive activity


San Diego, USA-based Amylin Pharmaceuticals (Nasdaq: AMLN) has filed a law suit against drug major Eli…

AmylinBoehringer IngelheimByettaDiabetesEli LillyLegallinagliptinPharmaceuticalTradjenta

400 to 424 of 429 results

Back to top